Generic Elucirem Availability
Last updated on May 7, 2025.
Elucirem is a brand name of gadopiclenol, approved by the FDA in the following formulation(s):
ELUCIREM (gadopiclenol - solution;intravenous)
-
Manufacturer: GUERBET
Approval date: September 21, 2022
Strength(s): 1.4553GM/3ML (485.1MG/ML) [RLD], 3.63825GM/7.5ML (485.1MG/ML) [RLD], 4.851GM/10ML (485.1MG/ML) [RLD], 7.2765GM/15ML (485.1MG/ML) [RLD], 14.553GM/30ML (485.1MG/ML) [RLD], 24.255GM/50ML (485.1MG/ML) [RLD], 48.51GM/100ML (485.1MG/ML) [RLD]
Is there a generic version of Elucirem available?
No. There is currently no therapeutically equivalent version of Elucirem available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elucirem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Gadolinium bearing PCTA-based contrast agents
Patent 10,973,934
Issued: April 13, 2021
Inventor(s): Napolitano Roberta & Lattuada Luciano & Baranyai Zsolt & Guidolin Nicole & Marazzi Giuseppe
Assignee(s): BRACCO IMAGING S.P.A.The present invention relates to the RRR/SSS pair of enantiomers of the of Gd(PCTA-tris-glutaric acid), the single enantiomers of the pair, the pharmaceutically acceptable salts thereof, their amide derivatives, and compositions comprising at least 50% of these compounds.
Patent expiration dates:
- August 6, 2039✓
- August 6, 2039
-
Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Patent 11,590,246
Issued: February 28, 2023
Inventor(s): Le Greneur; Soizic et al.
Assignee(s): GUERBET (Villepinte, FR)The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: ##STR00001##
The present invention also relates to a process for preparing and purifying said complex of formula (II), and also to a composition comprising said complex.Patent expiration dates:
- January 17, 2040✓
- January 17, 2040
-
Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Patent 8,114,863
Issued: February 14, 2012
Inventor(s): Port Marc
Assignee(s): GuerbetThe present invention relates to a compound of formula (II) chosen from (IIa) and (IIb) or of formula (VI) chosen from (VIa) and (VIb) of following general formulae:
Patent expiration dates:
- September 19, 2028✓
- September 19, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 21, 2027 - NEW CHEMICAL ENTITY
More about Elucirem (gadopiclenol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: magnetic resonance imaging contrast media
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.